Version 2 2020-05-06, 13:03Version 2 2020-05-06, 13:03
Version 1 2020-05-06, 13:00Version 1 2020-05-06, 13:00
journal contribution
posted on 2020-05-06, 13:03authored byLouise Wain
Although several genetic associations with scleroderma (SSc) are defined, very little is known on genetic susceptibility to SSc-associated interstitial lung disease (SSc-ILD). A number of common polymorphisms have been associated with SSc-ILD, but most have not been replicated in separate populations. Four SNPs in IRF5, and one in each of STAT4, CD226 and IRAK1, selected as having been previously the most consistently associated with SSc-ILD, were genotyped in 612 SSc patients, of European descent, of whom 394 had ILD. The control population (n = 503) comprised individuals of European descent from the 1000 Genomes Project. After Bonferroni correction, two of the IRF5 SNPs, rs2004640 (OR (95% CI)1.30 (1.10–1.54), pcorr = 0.015) and rs10488631 (OR 1.48 (1.14–1.92), pcorr = 0.022), and the STAT4 SNP rs7574865 (OR 1.43 (1.18–1.73), pcorr = 0.0015) were significantly associated with SSc compared with controls. However, none of the SNPs were significantly different between patients with SSc-ILD and controls. Two SNPs in IRF5, rs10488631 (OR 1.72 (1.24–2.39), pcorr = 0.0098), and rs2004640 (OR 1.39 (1.11–1.75), pcorr = 0.03), showed a significant difference in allele frequency between controls and patients without ILD, as did STAT4 rs7574865 (OR 1.86 (1.45–2.38), pcorr = 6.6 × 10−6). A significant difference between SSc with and without ILD was only observed for STAT4 rs7574865, being less frequent in patients with ILD (OR 0.66 (0.51–0.85), pcorr = 0.0084). In conclusion, IRF5 rs2004640 and rs10488631, and STAT4 rs7574865 were significantly associated with SSc as a whole. Only STAT4 rs7574865 showed a significant difference in allele frequency in SSc-ILD, with the T allele being protective against ILD.
Funding
This work was supported by Versus Arthritis (grant no. 20719). T.M. Maher is supported by an NIHR Clinician Scientist Fellowship (NIHR Ref: CS-2013-13-017) and a British Lung Foundation Chair in Respiratory Research (C17-3). P.L. Molyneaux is supported by an Action for Pulmonary Fibrosis Mike Bray fellowship. L.V. Wain is supported by a GSK/British Lung Foundation Chair in Respiratory Research (C17-1). The research was partially supported by the National Institute for Health Research (NIHR) Leicester Biomedical Research Centre; the views expressed are those of the author(s) and not necessarily those of the National Health Service (NHS), the NIHR or the Department of Health.
History
Citation
Stock, C.J.W., De Lauretis, A., Visca, D. et al. Defining genetic risk factors for scleroderma-associated interstitial lung disease. Clin Rheumatol 39, 1173–1179 (2020). https://doi.org/10.1007/s10067-019-04922-6
Version
VoR (Version of Record)
Published in
Clinical Rheumatology
Volume
39
Pagination
1173–1179
Publisher
Springer Verlag (Germany) for International League of Associations for Rheumatology (ILAR)
The data in this manuscript has been presented at
the European Respiratory Society Congress 2019 and at the British
Thoracic Society Winter 2019 meeting, conference proceedings not yet
published.
Electronic supplementary material The online version of this article
(https://doi.org/10.1007/s10067-019-04922-6) contains supplementary
material, which is available to authorized users.